Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 126
Filtrar
1.
J Cutan Pathol ; 49(1): 61-81, 2022 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-34622477

RESUMEN

BACKGROUND: Advances in molecular biology and genetics have contributed to breakthrough treatments directed at specific pathways associated with the development of cancer. Small-molecule inhibitors (Nibs) aimed at a variety of cellular pathways have been efficacious; however, they are associated with significant dermatologic toxicities. METHODS: We conducted a comprehensive review of dermatologic toxicities associated with Nibs categorized into the following five groups: (a) mitogen-activated protein kinase; (b) growth factor/multi-tyrosine kinase; (c) cell division/DNA repair; (d) signaling associated with myeloproliferative neoplasms; and (e) other signaling pathways. Prospective phase I, II, or III clinical trials, retrospective literature reviews, systematic reviews/meta-analyses, and case reviews/reports were included for analysis. RESULTS: Dermatologic toxicities reviewed were associated with every class of Nibs and ranged from mild to severe or life-threatening adverse skin reactions. Inflammatory reactions manifesting as maculopapular, papulopustular/acneiform, and eczematous lesions were frequent types of dermatologic toxicities seen with Nibs. Squamous cell carcinoma with keratoacanthoma-like features was associated with a subset of Nibs. Substantial overlap in dermatologic toxicities was found between Nibs. CONCLUSIONS: Dermatologic toxicities from Nibs are diverse and may overlap between classes of Nibs. Recognition of the various types of toxicities from Nibs is critical for patient care in the era of "oncodermatology/dermatopathology."


Asunto(s)
Antineoplásicos , Erupciones por Medicamentos , Inhibidores Enzimáticos , Neoplasias , Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Erupciones por Medicamentos/metabolismo , Erupciones por Medicamentos/patología , Inhibidores Enzimáticos/efectos adversos , Inhibidores Enzimáticos/uso terapéutico , Humanos , Neoplasias/tratamiento farmacológico , Neoplasias/metabolismo , Neoplasias/patología
3.
J Exp Med ; 218(12)2021 12 06.
Artículo en Inglés | MEDLINE | ID: mdl-34813654

RESUMEN

T cells possess distinguishing effector functions and drive inflammatory disorders. We have previously identified IL-5-producing Th2 cells as the pathogenic population predominantly involved in the pathology of allergic inflammation. However, the cell-intrinsic signaling pathways that control the pathogenic Th2 cell function are still unclear. We herein report the high expression of acetyl-CoA carboxylase 1 (ACC1) in the pathogenic CD4+ T cell population in the lung and skin. The genetic deletion of CD4+ T cell-intrinsic ACC1 dampened eosinophilic and basophilic inflammation in the lung and skin by constraining IL-5 or IL-3 production. Mechanistically, ACC1-dependent fatty acid biosynthesis induces the pathogenic cytokine production of CD4+ T cells via metabolic reprogramming and the availability of acetyl-CoA for epigenetic regulation. We thus identified a distinct phenotype of the pathogenic T cell population in the lung and skin, and ACC1 was shown to be an essential regulator controlling the pathogenic function of these populations to promote type 2 inflammation.


Asunto(s)
Acetil-CoA Carboxilasa/metabolismo , Erupciones por Medicamentos/patología , Neumonía/patología , Células Th2/patología , Acetil-CoA Carboxilasa/genética , Administración Tópica , Animales , Basófilos/metabolismo , Basófilos/patología , Linfocitos T CD4-Positivos/patología , Calcitriol/análogos & derivados , Calcitriol/toxicidad , Erupciones por Medicamentos/tratamiento farmacológico , Erupciones por Medicamentos/genética , Erupciones por Medicamentos/metabolismo , Ácidos Grasos/metabolismo , Factor Estimulante de Colonias de Granulocitos y Macrófagos/metabolismo , Interleucina-3/metabolismo , Interleucina-5/metabolismo , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Mutantes , Neumonía/genética , Neumonía/metabolismo , Células Th2/metabolismo
4.
Int J Mol Sci ; 22(14)2021 Jul 14.
Artículo en Inglés | MEDLINE | ID: mdl-34299145

RESUMEN

In accordance with the development of human technology, various medications have been speedily developed in the current decade. While they have beneficial impact on various diseases, these medications accidentally cause adverse reactions, especially drug eruption. This delayed hypersensitivity reaction in the skin sometimes causes a life-threatening adverse reaction, namely Stevens-Johnson syndrome and toxic epidermal necrolysis. Therefore, how to identify these clinical courses in early time points is a critical issue. To improve this problem, various biomarkers have been found for these severe cutaneous adverse reactions through recent research. Granulysin, Fas ligands, perforin, and granzyme B are recognized as useful biomarkers to evaluate the early onset of Stevens-Johnson syndrome and toxic epidermal necrolysis, and other biomarkers, such as miRNAs, high mobility group box 1 protein (HMGB1), and S100A2, which are also helpful to identify the severe cutaneous adverse reactions. Because these tools have been currently well developed, updates of the knowledge in this field are necessary for clinicians. In this review, we focused on the detailed biomarkers and diagnostic tools for drug eruption and we also discussed the actual usefulness of these biomarkers in the clinical aspects based on the pathogenesis of drug eruption.


Asunto(s)
Biomarcadores/análisis , Erupciones por Medicamentos/diagnóstico , Síndrome de Stevens-Johnson/diagnóstico , Animales , Diagnóstico Diferencial , Erupciones por Medicamentos/genética , Erupciones por Medicamentos/metabolismo , Humanos , Síndrome de Stevens-Johnson/genética , Síndrome de Stevens-Johnson/metabolismo
5.
Toxicol Lett ; 349: 145-154, 2021 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-34126182

RESUMEN

Cutaneous eruptions caused by the combination of Chinese and Western medicine have attracted widespread attention; however, the underlying mechanism remains unclear. This study aimed to evaluate the potential mechanism of cutaneous eruptions in vivo and in vitro using the combination of Shuanghuanglian injection powder (SHL) and aspirin (ASA) as an example. ASA and SHL co-administration induced inflammatory responses in HaCat cells, as evidenced by marked increases in the expression of IL-4 and TNF-α, and the level of apoptosis. Additionally, histopathological investigation of mice skin tissues showed local inflammatory cell infiltration. Western boltting was used to detect the effects of ASA on desmoglein-1 (DSG1) expression; we found that DSG1 expression was down-regulated in vivo and in vitro. Finally, the key components of SHL were administered to HaCat cells with down-regulated DSG1; it was seen that neochlorogenic acid and rutin have a significant effect on HaCat cell apoptosis. These results demonstrate that DSG1 deficiency is a potential cause of cutaneous eruptions caused by the combination of SHL and ASA, and neochlorogenic acid and rutin are the main allergenic components. This study provides a new research strategy for the safety evaluation of integrated traditional Chinese and Western medicine.


Asunto(s)
Apoptosis/efectos de los fármacos , Aspirina/toxicidad , Desmogleína 1/antagonistas & inhibidores , Erupciones por Medicamentos/etiología , Medicamentos Herbarios Chinos/toxicidad , Queratinocitos/efectos de los fármacos , Animales , Ácido Clorogénico/análogos & derivados , Ácido Clorogénico/toxicidad , Desmogleína 1/metabolismo , Erupciones por Medicamentos/metabolismo , Erupciones por Medicamentos/patología , Femenino , Células HaCaT , Humanos , Mediadores de Inflamación/metabolismo , Interleucina-4/metabolismo , Queratinocitos/metabolismo , Queratinocitos/patología , Ratones Endogámicos ICR , Ácido Quínico/análogos & derivados , Ácido Quínico/toxicidad , Rutina/toxicidad , Factor de Necrosis Tumoral alfa/metabolismo
6.
Am J Dermatopathol ; 43(10): 746-749, 2021 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-34086644

RESUMEN

ABSTRACT: Papillary dermal elastolysis has been described in the setting of experimental combination nivolumab and cabiralizumab immunotherapy. We report a third patient with distinctive, generalized atrophic macules that developed after a morbilliform eruption during a clinical trial for treatment of metastatic pancreatic adenocarcinoma. Histopathological findings demonstrated diminished elastic fibers in the papillary dermis, associated with a histiocyte-rich infiltrate and increased dermal mucin, features that should clue the dermatopathologist to this condition.


Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Erupciones por Medicamentos/patología , Neoplasias Pancreáticas/patología , Adenocarcinoma/secundario , Anticuerpos Monoclonales/administración & dosificación , Dermis/patología , Erupciones por Medicamentos/diagnóstico , Erupciones por Medicamentos/etiología , Erupciones por Medicamentos/metabolismo , Quimioterapia Combinada/efectos adversos , Tejido Elástico/patología , Histiocitos/patología , Humanos , Masculino , Persona de Mediana Edad , Mucinas/metabolismo , Nivolumab/administración & dosificación
8.
Sci Rep ; 11(1): 5493, 2021 03 09.
Artículo en Inglés | MEDLINE | ID: mdl-33750880

RESUMEN

Telaprevir used as a protease inhibitor against hepatitis C virus is frequently associated with cutaneous adverse reactions. To explore a histological biomarker of cutaneous adverse events induced by telaprevir, we systematically searched for genes that were dysregulated by telaprevir in normal human epidermal keratinocytes (NHEKs). Microarray analysis and real-time polymerase chain reaction (PCR) revealed the significant increase in the expression of S100 calcium-binding protein A2 (S100A2) gene following treatment of NHEKs with telaprevir. Immunohistochemical analysis demonstrated that the expression of S100A2 was dominant in the spinous layer of the epidermis in patients with telaprevir-mediated severe-type drug eruptions and limited to the basal layer of the epidermis in healthy subjects. Furthermore, S100A2 expression increased after treatment with trichloroethylene and other medications, and the degree of S100A2 expression correlated with the severity of cutaneous adverse events. S100A2 expression also significantly increased in the skin of patients with atopic dermatitis and psoriasis. Taken together, S100A2 is highly expressed in the epidermis under inflammatory conditions and drug eruptions and may serve as a marker for keratinocyte damage in response to any inflammatory or toxic condition.


Asunto(s)
Factores Quimiotácticos/biosíntesis , Erupciones por Medicamentos/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Queratinocitos/metabolismo , Oligopéptidos/farmacología , Proteínas S100/biosíntesis , Anciano , Erupciones por Medicamentos/patología , Femenino , Hepacivirus/metabolismo , Hepatitis C/tratamiento farmacológico , Hepatitis C/metabolismo , Hepatitis C/patología , Humanos , Queratinocitos/patología , Masculino , Persona de Mediana Edad
9.
Life Sci Alliance ; 3(6)2020 06.
Artículo en Inglés | MEDLINE | ID: mdl-32345660

RESUMEN

IL-36R signaling plays an important role in the pathogenesis of psoriasis. We ought to assess the specific function of IL-36R in keratinocytes for the pathology of Aldara-induced psoriasis-like dermatitis. Il36r ΔK mice presenting deletion of IL-36R in keratinocytes were similarly resistant to Aldara-induced ear inflammation as Il36r -/- mice, but acanthosis was only prevented in Il36r -/- mice. FACS analysis revealed that IL-36R signaling in keratinocytes is mandatory for early neutrophil infiltration in Aldara-treated ears. RNASeq and qRT-PCR experiments demonstrated the crucial role of IL-36R signaling in keratinocytes for induction of IL-23, IL-17, and IL-22 at early time points. Taken together, our results demonstrate that IL-36R signaling in keratinocytes plays a major role in the induction of Aldara-induced psoriasis-like dermatitis by triggering early production of IL-23/IL-17/IL-22 cytokines and neutrophil infiltration.


Asunto(s)
Erupciones por Medicamentos/inmunología , Interleucina-23/biosíntesis , Queratinocitos/inmunología , Otitis Externa/inmunología , Psoriasis/inmunología , Receptores de Interleucina-1/deficiencia , Transducción de Señal/genética , Administración Cutánea , Animales , Erupciones por Medicamentos/etiología , Erupciones por Medicamentos/metabolismo , Femenino , Eliminación de Gen , Imiquimod/administración & dosificación , Imiquimod/efectos adversos , Interleucina-17/biosíntesis , Interleucinas/biosíntesis , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Infiltración Neutrófila/efectos de los fármacos , Infiltración Neutrófila/genética , Otitis Externa/inducido químicamente , Psoriasis/inducido químicamente , Receptores de Interleucina-1/genética , Transducción de Señal/inmunología , Interleucina-22
10.
Phytomedicine ; 68: 153173, 2020 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-31999977

RESUMEN

BACKGROUND: Chrysoeriol is a flavone found in diverse dietary and medicinal herbs such as Lonicerae Japonicae Flos (the dried flower bud or newly bloomed flower of Lonicera japonica Thunb.). These herbs are commonly used for treating inflammatory diseases. Herbal extracts containing chrysoeriol have been shown to have anti-inflammatory effects and inhibit nuclear factor-kappa B (NF-κB) signaling. Some of these extracts can inhibit signal transducers and activators of transcription 3 (STAT3) signaling in cancer cells. PURPOSE: This study aimed to determine whether chrysoeriol has anti-inflammatory effects and whether NF-κB and STAT3 pathways are involved in the effects. STUDY DESIGN AND METHODS: A TPA (12-O-tetradecanoylphorbol-13-acetate)-induced ear edema mouse model and LPS-stimulated RAW264.7 cells were used to evaluate the effects of chrysoeriol. Griess reagent was used to measure the production of nitric oxide (NO). Western blot and enzyme-linked immunosorbent assays were employed to detect protein levels. RT-qPCR analyses were used to detect mRNA levels. Haematoxylin and eosin (H&E) staining was employed to examine the pathological conditions in animal tissues. RESULTS: In the mouse model, chrysoeriol ameliorated acute skin inflammation, evidenced by reduced ear thickness, ear weight and number of inflammatory cells in inflamed ear tissues. The compound lowered protein levels of phospho-p65 (Ser536), phospho-STAT3 (Tyr705), inducible nitric oxide synthases (iNOS), cyclooxygenase-2 (COX-2), interleukin 6 (IL-6), IL-1ß and tumor necrosis factor α (TNF-α) in mouse swollen ears. In LPS-stimulated RAW264.7 cells, chrysoeriol also lowered levels of these proteins. In addition, chrysoeriol decreased the production of NO and prostaglandin E2; inhibited the phosphorylation of inhibitor of κB (Ser32), p65 (Ser536) and Janus kinase 2 (Tyr1007/1008); decreased nuclear localization of p50, p65 and STAT3; and down-regulated mRNA levels of pro-inflammatory cytokines IL-6, IL-1ß and TNF-α that are transcriptionally regulated by NF-κB and STAT3 in the cell model. CONCLUSION: We for the first time demonstrated that chrysoeriol ameliorates TPA-induced ear edema in mice, and that inhibition of JAK2/STAT3 and IκB/p65 NF-κB pathways are involved in the anti-inflammatory effects of chrysoeriol. This study provides chemical and pharmacological justifications for the use of chrysoeriol-containing herbs in treating inflammatory diseases, and provides pharmacological groundwork for developing chrysoeriol as a novel anti-inflammatory agent.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Erupciones por Medicamentos/tratamiento farmacológico , Flavonas/farmacología , FN-kappa B/metabolismo , Factor de Transcripción STAT3/metabolismo , Animales , Citocinas/metabolismo , Modelos Animales de Enfermedad , Erupciones por Medicamentos/metabolismo , Erupciones por Medicamentos/patología , Regulación de la Expresión Génica , Proteínas I-kappa B/metabolismo , Lipopolisacáridos/toxicidad , Masculino , Ratones , Ratones Endogámicos ICR , Óxido Nítrico Sintasa de Tipo II/metabolismo , Células RAW 264.7 , Acetato de Tetradecanoilforbol/análogos & derivados , Acetato de Tetradecanoilforbol/toxicidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA